BIOMAT Database Logo BIOMAT Database Logo

Increased superoxide production by polymorphonuclear leukocytes in systemic lupus erythematosus. 1991

A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Alfredo Lanari Institute of Medical Research, Faculty of Medicine, University of Buenos Aires, Argentina.

Normal and lupus PMN show an enhancement in superoxide production in vitro when stimulated with lupus serum. When N-formyl-methionyl-leucyl-phenylalanine (FMLP) was used, lupus PMN showed an O2- production of 2.1 nmol/min/10(7) cells, which is 5.2 times the response of normal PMN stimulated by FMLP. Our results show the existence of serum factors in SLE patients that can stimulate O2- production by PMN. Lupus neutrophils showed an increased response to membrane stimuli such as FMLP, capable of triggering the cell respiratory burst. Lupus neutrophils appeared more responsive to membrane stimuli. The serum and cellular factors seemed to indicate an increase rate of superoxide production by PMN in lupus patients, which could be relevant factors in the development of vasculitis and tissue damage.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D002630 Chemotactic Factors Chemical substances that attract or repel cells. The concept denotes especially those factors released as a result of tissue injury, microbial invasion, or immunologic activity, that attract LEUKOCYTES; MACROPHAGES; or other cells to the site of infection or insult. Chemoattractant,Chemotactic Factor,Chemotaxin,Chemotaxins,Cytotaxinogens,Cytotaxins,Macrophage Chemotactic Factor,Chemoattractants,Chemotactic Factors, Macrophage,Macrophage Chemotactic Factors,Chemotactic Factor, Macrophage,Factor, Chemotactic,Factor, Macrophage Chemotactic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013481 Superoxides Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides. Superoxide Radical,Superoxide,Superoxide Anion
D016897 Respiratory Burst A large increase in oxygen uptake by neutrophils and most types of tissue macrophages through activation of an NADPH-cytochrome b-dependent oxidase that reduces oxygen to a superoxide. Individuals with an inherited defect in which the oxidase that reduces oxygen to superoxide is decreased or absent (GRANULOMATOUS DISEASE, CHRONIC) often die as a result of recurrent bacterial infections. Oxidative Burst,Burst, Oxidative,Burst, Respiratory,Bursts, Oxidative,Bursts, Respiratory,Oxidative Bursts,Respiratory Bursts

Related Publications

A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus.
January 2002, Immunological investigations,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Intrinsic endocytic function of polymorphonuclear leukocytes in systemic lupus erythematosus.
January 1984, Archivos de investigacion medica,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Superoxide production by polymorphonuclear leukocytes. A cytochemical approach.
January 1986, Histochemistry,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
[Functional activity of polymorphonuclear leukocytes in systemic lupus erythematosus and periarteritis nodosa].
January 1991, Revmatologiia (Moscow, Russia),
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
[Superoxide anion (O2-) production by polymorphonuclear leukocytes in diabetics].
June 1983, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Vitamin E decreases superoxide anion production by polymorphonuclear leukocytes.
March 1988, Pediatric research,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Nitric oxide inhibits superoxide production by inflammatory polymorphonuclear leukocytes.
March 1998, The American journal of physiology,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Dopamine inhibition of superoxide anion production by polymorphonuclear leukocytes.
May 1989, The Journal of allergy and clinical immunology,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Increased production of superoxide anion by neonatal polymorphonuclear leukocytes stimulated with a chemotactic peptide.
March 1988, American journal of hematology,
A M Casellas, and A Prat, and A Llera, and J Manni, and A Boveris, and J F Sarano
Superoxide production by peripheral polymorphonuclear leukocytes in patients with COPD.
April 2003, Respiratory medicine,
Copied contents to your clipboard!